Table 2.
Baseline Characteristics of the Patients Grouped by the Number of irAEs
| Characteristic | Multiple (n = 42) |
Single (n = 66) |
P value* |
|---|---|---|---|
| Age at administration, years | |||
| Median (Range) | 66 (34–86) | 67 (36–94) | 0.39 |
| Male gender, n (%) | 23 (55) | 48 (73) | 0.06 |
| ECOG performance status, n (%) | |||
| 0–1 | 40 (95) | 60 (91) | 0.51 |
| ≥2 | 2 (5) | 6 (9) | |
| Treatment line, n (%) | |||
| 1st line | 10 (24) | 12 (18) | 0.62 |
| 2nd line or later | 32 (76) | 54 (82) | |
| Cancer types, n (%) | |||
| Non-small-cell lung cancer | 25 (60) | 38 (58) | 0.82 |
| Malignant melanoma | 8 (19) | 10 (15) | |
| Renal cell cancer | 6 (14) | 10 (15) | |
| Gastric cancer | 3 (7) | 8 (12) | |
| Type of ICIs, n (%) | |||
| Nivolumab | 30 (71) | 53 (80) | 0.56 |
| Pembrolizumab | 11 (26) | 12 (18) | |
| Atezolizumab | 1 (2) | 1 (2) | |
| Median duration of ICI administration, months (range) | 8.6 (0.04–46.0) |
4.0 (0.04–44.5) |
0.13 |
Notes: *A t-test for difference in means was used to compare ages and median durations of ICI administration; all other variables were compared using Chi-Square and Fisher’s Exact tests.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitors: irAEs, immune-related adverse events.